Background And Objective: Predicting the malignant potential of breast lesions based on breast ultrasound (BUS) images is a crucial component of computer-aided diagnosis system for breast cancers. However, since breast lesions in BUS images generally have various shapes with relatively low contrast and present complex textures, it still remains challenging to accurately identify the malignant potential of breast lesions.
Methods: In this paper, we propose a multi-scale gradational-order fusion framework to make full advantages of multi-scale representations incorporating with gradational-order characteristics of BUS images for breast lesions classification. Specifically, we first construct a spatial context aggregation module to generate multi-scale context representations from the original BUS images. Subsequently, multi-scale representations are efficiently fused in feature fusion block that is armed with special fusion strategies to comprehensively capture morphological characteristics of breast lesions. To better characterize complex textures and enhance non-linear modeling capability, we further propose isotropous gradational-order feature module in the feature fusion block to learn and combine multi-order representations. Finally, these multi-scale gradational-order representations are utilized to perform prediction for the malignant potential of breast lesions.
Results: The proposed model was evaluated on three open datasets by using 5-fold cross-validation. The experimental results (Accuracy: 85.32%, Sensitivity: 85.24%, Specificity: 88.57%, AUC: 90.63% on dataset A; Accuracy: 76.48%, Sensitivity: 72.45%, Specificity: 80.42%, AUC: 78.98% on dataset B) demonstrate that the proposed method achieves the promising performance when compared with other deep learning-based methods in BUS classification task.
Conclusions: The proposed method has demonstrated a promising potential to predict malignant potential of breast lesion using ultrasound image in an end-to-end manner.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2023.107346 | DOI Listing |
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Cancer Genet
January 2025
Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; Rutgers Cancer Institute, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Collision tumors, characterized by the coexistence of two unique neoplasms in close approximation, are rare and pose diagnostic challenges. This is particularly true when the unique neoplasms are of the same histologic type. Here we report such a case where comprehensive tumor profiling by next generation sequencing (NGS) as well as immunohistochemistry revealed two independent adenocarcinomas comprising what was initially diagnosed as a single adenocarcinoma of the gastroesophageal (GEJ) junction.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
George M. Rodgers, MD, PhD, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; and Jeffrey A. Gilreath, PharmD, Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, Department of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
J Clin Oncol
January 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Colorectal cancer (CRC) remains a major global health burden, being one of the most prevalent cancers with high mortality rates. Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Guangdong Provincial Key Laboratory of Luminescence from Molecular Aggregates, State Key Laboratory of Luminescent Materials and Devices, School of Materials Science and Engineering, AIE Institute, South China University of Technology, Guangzhou, 510640, China.
Photodynamic therapy holds great potentials in cancer treatment, yet its effectiveness in hypoxic solid tumor is limited by the oxygen-dependence and insufficient oxidative potential of conventional type II reactive oxygen species (ROS). Herein, the study reports a supramolecular photosensitizer, BSA@TPE-BT-SCT NPs, through encapsulating aggregation-enhanced emission photosensitizer by bovine serum albumin (BSA) to significantly enhance ROS, particularly less oxygen-dependent type I ROS for photodynamic immunotherapy. The abundant type I ROS generated by BSA@TPE-BT-SCT NPs induce multiple forms of programmed cell death, including apoptosis, pyroptosis, and ferroptosis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!